Literature DB >> 17278097

Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden.

Tanja Stocks1, Annekatrin Lukanova, Sabina Rinaldi, Carine Biessy, Laure Dossus, Bernt Lindahl, Göran Hallmans, Rudolf Kaaks, Pär Stattin.   

Abstract

Factors related to insulin resistance have been implicated in prostate cancer development, however, few analytical studies support such an association. We performed a case control study on 392 prostate cancer cases and 392 matched controls nested in a prospective cohort in Northern Sweden. Plasma concentrations of C-peptide, leptin, glycated haemoglobin (HbA1c) and fasting and post-load glucose were analysed and homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Conditional logistic regression analyses were used to calculate odds ratios (OR) of prostate cancer. High levels of C-peptide, HOMA-IR, leptin and HbA1c were associated with significant decreases in risk of prostate cancer, with ORs for top vs. bottom quartile for C-peptide of 0.59 (95% Confidence Interval [CI], 0.40-0.89; p(trend) = 0.008), HOMA-IR 0.60 (95% CI, 0.38-0.94; p(trend) = 0.03), leptin 0.55 (95% CI, 0.36-0.84; p(trend) = 0.006) and HbA1c 0.56 (95% CI, 0.35-0.91; p(trend) = 0.02). All studied factors were strongly inversely related to risk among men less than 59 years of age at blood sampling, but not among older men, with a significant heterogeneity between the groups for leptin (p(heterogeneity) = 0.006) and fasting glucose (p(heterogeneity) = 0.03). C-peptide and HOMA-IR were strongly inversely related to non-aggressive cancer but were non-significantly positively related to risk of aggressive disease (p(heterogeneity) = 0.007 and 0.01, respectively). Our data suggest that androgens, which are inversely associated with insulin resistance, are important in the early prostate cancer development, whereas insulin resistance related factors may be important for tumour progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278097     DOI: 10.1002/ijc.22587

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Marian L Neuhouser; Cathee Till; Alan Kristal; Phyllis Goodman; Ashraful Hoque; Elizabeth A Platz; Ann W Hsing; Demetrius Albanes; Howard L Parnes; Michael Pollak
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

Review 3.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

Authors:  Yin Cao; Katharina Nimptsch; Irene M Shui; Elizabeth A Platz; Kana Wu; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2014-11-10       Impact factor: 7.396

Review 5.  A stage-dependent link between metabolic syndrome components and incident prostate cancer.

Authors:  Jan Hammarsten; Jan-Erik Damber; Mohammad A Haghsheno; Dan Mellström; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

6.  Metabolic imbalance and prostate cancer progression.

Authors:  Anya J Burton; Kate M Tilling; Jeff M Holly; Freddie C Hamdy; Mari-Anne E Rowlands; Jenny L Donovan; Richard M Martin
Journal:  Int J Mol Epidemiol Genet       Date:  2010-07-25

7.  Obesity-related markers and breast cancer in CPS-II Nutrition Cohort.

Authors:  Mia M Gaudet; Alpa V Patel; Lauren R Teras; Juzhong Sun; Peter T Campbell; Victoria L Stevens; Eric J Jacobs; Susan M Gapstur
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

8.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

9.  Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.

Authors:  Demetrius Albanes; Stephanie J Weinstein; Margaret E Wright; Satu Männistö; Paul J Limburg; Kirk Snyder; Jarmo Virtamo
Journal:  J Natl Cancer Inst       Date:  2009-08-21       Impact factor: 13.506

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.